BioCentury | Jul 10, 2014
Distillery Therapeutics

Indication: Cancer

...steps could include designing small molecule-based strategies to inhibit MAO-A in patients with prostate cancer. Krenitsky Pharmaceuticals Inc....
BioCentury | Feb 21, 2011
Clinical News

CXB909: Phase I data

...neuropathies and neurodegenerative disorders (see BioCentury, June 22, 2009). CeNeRx BioPharma Inc. , Cary, N.C. Krenitsky Pharmaceuticals Inc....
BioCentury | Feb 14, 2011
Clinical News

CXB909: Phase I start

...neuropathies and neurodegenerative disorders (see BioCentury, June 22, 2009). CeNeRx BioPharma Inc. , Cary, N.C. Krenitsky Pharmaceuticals Inc....
BioCentury | Jan 10, 2011
Clinical News

TriRima: Phase II started

...rights to TriRima from Krenitsky under a 2005 deal. CeNeRx BioPharma Inc. , Cary, N.C. Krenitsky Pharmaceuticals Inc....
BioCentury | Aug 13, 2010
Financial News

CeNeRx raises $13 million

...that elevates the levels of serotonin, norepinephrine and dopamine. CeNeRx has rights to TriRima from Krenitsky Pharmaceuticals Inc....
BioCentury | Jun 22, 2009
Company News

CeNeRx, Krenitsky Pharmaceuticals deal

...rights to TriRima from Krenitsky under a 2005 deal. CeNeRx BioPharma Inc. , Cary, N.C. Krenitsky Pharmaceuticals Inc....
Items per page:
1 - 6 of 6
BioCentury | Jul 10, 2014
Distillery Therapeutics

Indication: Cancer

...steps could include designing small molecule-based strategies to inhibit MAO-A in patients with prostate cancer. Krenitsky Pharmaceuticals Inc....
BioCentury | Feb 21, 2011
Clinical News

CXB909: Phase I data

...neuropathies and neurodegenerative disorders (see BioCentury, June 22, 2009). CeNeRx BioPharma Inc. , Cary, N.C. Krenitsky Pharmaceuticals Inc....
BioCentury | Feb 14, 2011
Clinical News

CXB909: Phase I start

...neuropathies and neurodegenerative disorders (see BioCentury, June 22, 2009). CeNeRx BioPharma Inc. , Cary, N.C. Krenitsky Pharmaceuticals Inc....
BioCentury | Jan 10, 2011
Clinical News

TriRima: Phase II started

...rights to TriRima from Krenitsky under a 2005 deal. CeNeRx BioPharma Inc. , Cary, N.C. Krenitsky Pharmaceuticals Inc....
BioCentury | Aug 13, 2010
Financial News

CeNeRx raises $13 million

...that elevates the levels of serotonin, norepinephrine and dopamine. CeNeRx has rights to TriRima from Krenitsky Pharmaceuticals Inc....
BioCentury | Jun 22, 2009
Company News

CeNeRx, Krenitsky Pharmaceuticals deal

...rights to TriRima from Krenitsky under a 2005 deal. CeNeRx BioPharma Inc. , Cary, N.C. Krenitsky Pharmaceuticals Inc....
Items per page:
1 - 6 of 6